QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)

Pacira BioSciences (PCRX) Stock Price, News & Analysis

$29.55
+0.51 (+1.76%)
(As of 01:16 PM ET)
Today's Range
$28.86
$29.55
50-Day Range
$27.70
$33.07
52-Week Range
$25.93
$48.60
Volume
164,759 shs
Average Volume
503,765 shs
Market Capitalization
$1.37 billion
P/E Ratio
36.48
Dividend Yield
N/A
Price Target
$49.50

Pacira BioSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
69.5% Upside
$49.50 Price Target
Short Interest
Bearish
8.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
1.50mentions of Pacira BioSciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.79 M Sold Last Quarter
Proj. Earnings Growth
29.82%
From $2.18 to $2.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

9th out of 939 stocks

Pharmaceutical Preparations Industry

4th out of 433 stocks

PCRX stock logo

About Pacira BioSciences Stock (NASDAQ:PCRX)

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

PCRX Stock Price History

PCRX Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
PCRX Apr 2024 22.500 put
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Navigating 4 Analyst Ratings For Pacira BioSciences
Q4 2023 Pacira Biosciences Inc Earnings Call
Preview: Pacira BioSciences's Earnings
Pacira BioSciences Q4 2023 Earnings Preview
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
712
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.50
High Stock Price Target
$57.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+70.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$41.96 million
Pretax Margin
9.14%

Debt

Sales & Book Value

Annual Sales
$674.98 million
Cash Flow
$4.03 per share
Book Value
$18.74 per share

Miscellaneous

Free Float
43,432,000
Market Cap
$1.35 billion
Optionable
Optionable
Beta
0.76
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

PCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price target for 2024?

10 Wall Street analysts have issued 12-month price targets for Pacira BioSciences' stock. Their PCRX share price targets range from $42.00 to $57.00. On average, they expect the company's share price to reach $49.50 in the next twelve months. This suggests a possible upside of 69.5% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2024?

Pacira BioSciences' stock was trading at $33.74 on January 1st, 2024. Since then, PCRX stock has decreased by 13.4% and is now trading at $29.21.
View the best growth stocks for 2024 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Thursday, February, 29th. The company reported $0.71 EPS for the quarter, meeting the consensus estimate of $0.71. The business earned $181.24 million during the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a trailing twelve-month return on equity of 12.81% and a net margin of 6.22%.

What ETFs hold Pacira BioSciences' stock?
What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $680.0 million-$705.0 million, compared to the consensus revenue estimate of $722.5 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.98%), Vanguard Group Inc. (10.96%), Frontier Capital Management Co. LLC (4.49%), Dimensional Fund Advisors LP (3.04%), Stephens Investment Management Group LLC (2.84%) and Vestal Point Capital LP (2.58%). Insiders that own company stock include Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners